Priority Health to cover FoundationOne genomic profiles

In The Headlines: A good week for NIH, a bad week for Vinay Prasad

While doing somewhat-routine reporting on this year’s Senate Appropriations Committee bills, Paul Goldberg, editor and publisher of The Cancer Letter, quickly realized that he was seeing a full bipartisan rejection of President Donald J. Trump’s plan to defund and therefore dismantle biomedical research in the United States.

August 06, 2025

Vol.51 No.30

Capitol Hill

GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise

Bits of good news for NIH flickered consistently over the past week.

Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies?

It’s not a good week to be Vinay Prasad.

August 01, 2025

Vol.51 No.30

By Claire Marie Porter

U.S. News & World Report expands evaluation of outcomes in cancer subspecialties

Those anxiously anticipating the release of the U.S. News & World Report‘s evaluation of cancer hospitals will find one intriguing change.

USPSTF doesn’t lean right or left—it’s about data, not politics

Multiple components of the healthcare and public health systems are currently under scrutiny. One of them is reportedly the U.S. Preventive Services Task Force (USPSTF: “Task Force”), established in 1984 and managed by the Agency for Healthcare Research and Quality. It was created to maintain an ongoing evaluation of disease prevention and screening interventions that...

UPenn study supports continued use of ODAC voting

A study led by researchers at the University of Pennsylvania has found that binary (yes/no) voting at the FDA Oncologic Drugs Advisory Committee can accurately capture the committee members’ perspectives in most cases.

August 01, 2025

Vol.51 No.30

By Jacquelyn Cobb

Priority Health to cover FoundationOne genomic profiles

YOU MAY BE INTERESTED IN

In The Headlines: A good week for NIH, a bad week for Vinay Prasad

GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise

Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies?

U.S. News & World Report expands evaluation of outcomes in cancer subspecialties

USPSTF doesn’t lean right or left—it’s about data, not politics

UPenn study supports continued use of ODAC voting

Renew today!

Subscriber content

Never miss an issue!

Login

Priority Health to cover FoundationOne genomic profiles

YOU MAY BE INTERESTED IN

In The Headlines: A good week for NIH, a bad week for Vinay Prasad

GOP-led Congress rejects Trump’s plans to gut medical researchSenate bill gives NIH a $400 million raise

Vinay Prasad falls from grace at FDA upon flunking Trump political purity testMAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies?

U.S. News & World Report expands evaluation of outcomes in cancer subspecialties

USPSTF doesn’t lean right or left—it’s about data, not politics

UPenn study supports continued use of ODAC voting

Never miss an issue!

Login

GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise

Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies?